Independent research · not medical adviceSources dated · terms can change

LOW-risk evidence brief

Zepbound vs. Wegovy without insurance: a dated self-pay comparison

By Izaiah Tilton · Independent research · every claim source-cited · updated 2026-07-23

Generated editorial evidence map for Zepbound vs. Wegovy without insurance: a dated self-pay comparison
Reviewed against FDA prescribing information and peer-reviewed studies where applicable · Sources checked 2026-07-23 · General information only, not medical advice.

Direct answer

Without insurance, there is no universal price. As of 2026-07-23, Lilly listed Zepbound at $499 to $1,086.37 per fill at list price and $299 to $699 through direct self-pay, depending on dose and presentation. NovoCare listed Wegovy prices by formulation, dose, channel, and offer window, including $199 for eligible new patients' first two specified injection fills and standard injection prices of $349 or $399. These manufacturer terms are conditional, not guaranteed. Add membership, intake, follow-up, lab, supply, shipping, and renewal charges when comparing totals.

Put every quoted price in the right lane

Several valid numbers for Zepbound or Wegovy can still produce a bad comparison. List price, direct self-pay, an introductory fill, and a standard recurring fill describe different transactions. The manufacturer figures here were checked on 2026-07-23 and depend on the product, presentation, dose, channel, eligibility, and time window. Put those labels beside every number before adding separate service charges.

Track list price, manufacturer self-pay price, and final all-in cost separately. List price is a reference, not a checkout promise. Self-pay prices are conditional commercial terms. All-in cost includes medication and any membership, intake, follow-up, lab, supply, shipping, or renewal charge that leaves the household budget. Compare the current written terms for the exact fill and every fee beside the medication amount, rather than choosing a brand from one headline number.

Lilly defines list price as wholesale acquisition cost, what the manufacturer charges wholesalers. Patient cost can differ because of insurance cost sharing, pharmacy charges, discounts, or assistance. Even without insurance, a pharmacy cash quote may differ from list price, and direct-to-patient pricing may cover only a specified presentation. Neither the largest reference price nor the lowest program figure is an automatic cash price for everyone.

Savings cards are a third category. A commercial copay offer may require qualifying insurance and primary-insurance processing; self-pay can operate outside insurance. Similar phrases such as savings, starting at, or pay as little as can produce different administrative and financial consequences. Record the offer, insurance lane, fill definition, maximum benefit, eligibility conditions, and expiration. If checkout labels the transaction differently from the reviewed terms, clarify the route before paying.

What the manufacturers published on 2026-07-23

Lilly's official page listed Zepbound at $499 to $1,086.37 per fill and defined a month as 28 days. It said patient cost depends largely on prescription-drug insurance, pharmacy charges, discounts, or assistance. Without insurance, treat this range as context, not proof that a shopper owes its low end, high end, or any point between them. Identify the product presentation and purchase channel before comparing it with another quote.

The page listed direct-to-patient self-pay prices for specified four-count single-dose vial or single-patient-use KwikPen presentations: $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, or 15 mg. These dated terms neither recommend a dose nor promise a prescription, program eligibility, stock, or that nothing else is owed. Record the presentation, dose, quantity, pharmacy channel, and current terms; direct pricing differs from wholesale acquisition cost.

NovoCare listed Wegovy self-pay terms by dose and channel. Patients new to the savings offer or NovoCare Pharmacy could pay $199 for each of their first two 0.25 mg or 0.5 mg injection fills through 2026-12-31. One injection month meant four pens, or 28 days. Standard prices were $349 per month for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 for Wegovy HD 7.2 mg. Eligibility and restrictions apply; Novo Nordisk may modify or cancel the program.

For Wegovy tablets, NovoCare listed $149 per month for 1.5 mg; $149 for 4 mg through 2026-08-31, then $199; and $299 for 9 mg or 25 mg. One tablet month meant a 30-tablet bottle. Do not blend these with injection prices in an unlabeled range. Formulation, dose, fill definition, introductory status, and deadline matter. Recheck the official table on purchase day because the manufacturer retained change and cancellation rights. These prices don't establish prescription access, stock availability, or a zero balance for separate program charges. Confirm the checkout amount before paying.

Why the lowest figures are not directly comparable

Align the rows before comparing prices. Zepbound's $299 starting point covered a specified 2.5 mg presentation. Wegovy's $199 introductory injection price covered eligible new patients, specified doses, two 28-day fills, and a stated deadline. Standard Wegovy injections cost $349 or $399, while tablets used another schedule and a 30-tablet month. Ranking $199, $299, $349, and $699 without these labels mixes offer stages, formulations, doses, and fill definitions.

Define the prescribed product, formulation, presentation, dose, quantity, channel, new-patient or standard status, and time horizon. Compare first-fill and steady-state totals separately; an introductory amount may lower today's cash requirement but says little about later fills, while a higher number may represent a different presentation or standard schedule. The cited evidence does not determine the appropriate medication, formulation, or dose. Its commercial conclusion is limited: don't call either brand cheaper for a person until current like-for-like quotes and all separate fees are documented.

Savings cards and self-pay follow different rules

Manufacturer savings floors are not guaranteed cash amounts. Commercial copay offers may require eligible commercial coverage, a valid prescription, correct pharmacy processing, and compliance with fill or monthly limits; government-program exclusions and other restrictions may apply. Manufacturers can change or end offers. Downloading a card or completing enrollment doesn't prove the next fill will reach the advertised floor. Check current terms and the pharmacy's final adjudicated amount each time.

Self-pay offers may operate outside insurance, prohibit reimbursement submissions, and prevent a purchase from counting toward a deductible or true out-of-pocket obligation. A lower checkout amount may therefore leave insurance thresholds unchanged. Keep the offer terms and receipt; don't submit or describe the transaction in a way those terms prohibit. Use the savings-card guide for a term-by-term workflow; here, record the financial effect rather than assuming a discount works like coverage.

A manufacturer medication price is not necessarily an all-in telehealth price. Online services may charge for intake, membership, follow-up access, labs, supplies, shipping, or administration. The cited sources provide no universal amounts for these categories, so an unstated fee is unknown, not zero. Ask whether each charge is included in the displayed medication amount, billed separately, temporarily waived, or triggered by refill or renewal, and get the answer in writing before paying.

Calculate the first-fill total, including everything due before or with the first order, and the steady-state total, using the regular medication price plus recurring fees. Add the full obligation if there is a minimum term. Keep shipping and supplies separate; direct delivery doesn't prove they are free. The online GLP-1 program cost page offers broader context, but checkout and current written terms control the individual budget.

Add care and fulfillment charges to the medication price

Card acceptance, manufacturer terms, qualified-expense treatment, documentation, and a plan administrator's decision are separate issues. Accepting an account card doesn't guarantee approval or reimbursement, and it doesn't turn self-pay into an insurance claim. Some reviewed manufacturer terms prohibit reimbursement from a healthcare reimbursement account for purchases under a particular self-pay offer. The exact offer document controls, not a merchant's general HSA or FSA statement.

The cited sources provide no tax advice and can't predict an administrator's decision. Before relying on account funds, identify the charge and self-pay terms, obtain an itemized receipt, and ask the applicable administrator about documentation and restrictions. List medication, membership, labs, and other charges separately because treatment may differ. Provider payment-tool marketing doesn't override a reimbursement prohibition in manufacturer terms. Unless controlling sources support another treatment, budget the full cash outlay.

Before paying, verify brand, formulation, presentation, dose, quantity, days supplied, offer name, new-patient or standard status, channel, deadline, amount due today, and the post-introductory recurring amount. Add rows for membership, intake, follow-up, labs, supplies, shipping, taxes or other charges, minimum commitment, renewal, and cancellation. Mark each field confirmed, conditional, or unknown; a blank doesn't mean free.

Save the dated manufacturer page, full offer terms, pre-payment checkout summary, pharmacy quote, program terms, and written fee answers. FDA advises using a state-licensed online pharmacy that requires a valid prescription and offers access to a licensed pharmacist. Confirm the dispensing pharmacy, not only the telehealth brand. Keep this checklist private; don't send Clinic Scout prescription, insurance, payment, or health information. Recheck every refill because offer windows, eligibility, channel availability, and commercial fees can change.

Keep HSA and FSA questions separate from insurance

Set a common period: 28 or 30 days, three fills, or the full minimum commitment. Use quotes for exact prescribed products and label differences in formulation, presentation, dose, and supply. Separate medication from provider administration and model introductory and standard prices. Record whether self-pay operates outside insurance or prohibits deductible, out-of-pocket, or reimbursement treatment. Add evidence and expiration dates so stale offers don't anchor the choice.

Compare commercial fit only after completing the checklist. Priorities may include first-fill cash cost, a stable recurring amount, fewer fees, or clearer cancellation. Treat unknowns as uncertainty, not savings; pause or choose neither quote if a material field remains unresolved. Product choice, dose, eligibility, and clinical risks are outside this no-clinician guide. The evidence-first provider page compares documented commercial processes, while the insurance-support-versus-self-pay page preserves the payment-path distinction.

Build a like-for-like budget before paying

Misleading comparisons pair an introductory fill with a recurring price without labeling the periods, or treat different formulations, doses, presentations, or supply definitions as identical. Other errors treat list price as the inevitable cash bill, apply a manufacturer self-pay amount to every pharmacy, or omit membership, intake, follow-up, lab, supply, shipping, or renewal because a landing page is silent. These shortcuts create unsupported cheapest-option claims.

After enrollment, buyers may assume self-pay counts toward a deductible, reuse an expired offer, treat one successful fill as a guarantee, or confuse card enrollment with eligibility. A telehealth page may display only medication cost while checkout adds a separate service obligation, and search results may show stale figures. Return to current first-party terms, identify the transaction lane, obtain the final amount before paying, preserve the evidence, and maintain a fallback budget without assistance.

Is Zepbound $299 without insurance? On 2026-07-23, Lilly listed $299 for the specified 2.5 mg direct-to-patient vial or KwikPen self-pay presentation, not every dose, presentation, pharmacy, or person. Other doses were $399, $499, or $699. Is Wegovy $199? NovoCare listed $199 for eligible new patients' first two 28-day 0.25 mg or 0.5 mg injection fills through 2026-12-31; standard injections were $349 or $399 by dose. Recheck all terms.

Which costs less? The sources name no universal winner because the lowest prices cover different products and conditions. Do self-pay purchases count toward a deductible? Reviewed terms may prohibit applying them to deductibles or true out-of-pocket obligations. Are telehealth fees included? Not necessarily; request itemized membership, intake, follow-up, lab, supply, shipping, and renewal charges. Will prices remain? Neither manufacturer promises permanence, so recheck rights, eligibility, dates, and restrictions for every transaction.

Questions to resolve before relying on a quote

The cited evidence uses first-party pages checked on 2026-07-23. Lilly supplied Zepbound's list-price range, direct-to-patient dose schedule, WAC distinction, and changeable savings terms. NovoCare supplied Wegovy prices by formulation, dose, channel, and time, plus eligibility terms, fill definitions, deadlines, and change rights. FDA online-pharmacy guidance, updated 2025-01-02, supports checking for a valid prescription and state-licensed pharmacy.

Use the online GLP-1 program cost page for broader line-item comparisons, the insurance-support-versus-self-pay page for payment-path boundaries, and the evidence-first provider page for documented program processes. They don't replace a current manufacturer offer, pharmacy quote, or checkout summary.

Sources

  1. Eli Lilly and Company · supports zepbound-list-price-range, zepbound-direct-self-pay-prices, manufacturer-offer-conditions, self-pay-insurance-boundary · checked 2026-07-23
  2. Novo Nordisk NovoCare · supports wegovy-injection-self-pay-prices, wegovy-tablet-self-pay-prices, manufacturer-offer-conditions, self-pay-insurance-boundary · checked 2026-07-23
  3. U.S. Food and Drug Administration · supports valid-prescription-pharmacy-check · checked 2026-07-23

Next step

Treat the dated manufacturer price as a starting point. Verify the product, presentation, dose, channel, offer window, amount due today, recurring amount, and separate fees in writing. Compare first-fill and steady-state totals over the same period, and budget for an offer that expires, changes, or becomes unavailable. The cited evidence does not select medication or determine eligibility.

Compare your priorities privately